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Introduction {#jcsm12074-sec-0005}
============

Although resistance exercise is crucial for sarcopenia prevention,[1](#jcsm12074-bib-0001){ref-type="ref"} poor compliance related with low motivation and physical capacity in elderly people are challenges.[2](#jcsm12074-bib-0002){ref-type="ref"} To overcome these issues, several drugs[3](#jcsm12074-bib-0003){ref-type="ref"}, [4](#jcsm12074-bib-0004){ref-type="ref"} and anabolic hormones[5](#jcsm12074-bib-0005){ref-type="ref"} have been introduced as exercise mimetics. However, hormones have systemic and metabolic adverse effects,[6](#jcsm12074-bib-0006){ref-type="ref"} and newly introduced exercise mimetics await multiple phases of pre‐clinical and clinical trials. At present, it appears more promising to find connections between an existing drug product to sarcopenia---drug repositioning or drug repurposing.[7](#jcsm12074-bib-0007){ref-type="ref"} Because extensive information on the pharmacology and toxicity of repositioned drugs is available, their clinical use may be safer than that of newly developed drugs.[8](#jcsm12074-bib-0008){ref-type="ref"}

There was a report that 4,4′‐diamino‐diphenyl sulfone (DDS), a sulfonamide antibiotic and a longtime treatment of choice for leprosy, prolonged lifespan and increased mobility in nematodes.[9](#jcsm12074-bib-0009){ref-type="ref"} Reduction in levels of reactive oxygen species and inhibition of muscular pyruvate kinase activity by DDS were proposed as the mechanisms underlying the increase in longevity in the animal model. These metabolic effects were replicated in mouse muscle tissue. Notably, compared with controls, DDS‐treated aged worms showed significantly faster body movements, which lead us to hypothesize that DDS may have sarcopenia‐preventive effects in humans.

An interesting phenomenon was noted in the authors\' country that many leprosy survivors living in specialized colonies continue to take DDS, at varying doses, for a long time after their diseases have been eradicated, probably owing to an irrational fear of disease recurrence. This peculiar situation provides an opportunity to investigate the anti‐sarcopenic effects of DDS in humans. To our knowledge, whether long‐term DDS treatment alters sarcopenic status among leprosy survivors has not been previously investigated, although leprosy survivors are at a greater risk of developing sarcopenia than healthy individuals.[10](#jcsm12074-bib-0010){ref-type="ref"}

We aimed to compare skeletal muscle mass and strength in leprosy survivors who had been taking DDS to those who had not. DDS‐taking leprosy survivors were compared with survivors not taking DDS with respect to body composition, muscular strength, functional performance, and activity levels. Dose--response relationships between the total lifetime DDS exposure and muscle mass/strength were also analysed. We hypothesized that DDS‐taking elderly female leprosy survivals would show greater skeletal muscle mass and strength than non‐takers.

Methods {#jcsm12074-sec-0006}
=======

Participants {#jcsm12074-sec-0007}
------------

A cross‐sectional study was performed at a local leprosy rehabilitation hospital in Yeosu, South Korea, between March 2012 and September 2013. At the time of the study, 82 female leprosy survivors resided in two leprosy villages (Dosung and Yeochun) affiliated with the hospital. Among them, 46 were elderly (aged 65 years or older) and ambulatory with mild or no physical impairment of the limbs. Survivors who had systemic or structural disorders that affected mobility or body composition, amputation proximal to the level of the wrist or ankle joint as a leprosy sequela, a history of central nervous system disease such as cerebrovascular accident or spinal cord injury, or a surgical history that could disturb the analysis of body composition (e.g. joint arthroplasty) were excluded. After five patients were excluded due to a history of arthroplasty (*n* = 3), cerebrovascular accident (*n* = 1), and poor cooperation (*n* = 1), 41 survivors were recruited (*Figure* [1](#jcsm12074-fig-0001){ref-type="fig"}). This study was approved by the institutional review board of our hospital (IRB No. H‐1109‐078‐378). Written informed consents were obtained from all female leprosy survivors.

![Flow diagram of participant recruitment. DDS, 4,4′‐diamino‐diphenyl sulfone.](JCSM-7-322-g001){#jcsm12074-fig-0001}

Medical history {#jcsm12074-sec-0008}
---------------

The medical history of the participants was obtained by one‐on‐one interviews to assess whether they had been taking DDS (dapsone) for the past year or longer, when they were diagnosed with leprosy, when they started DDS medication at a therapeutic dosage (100 mg/day), when they switched to a self‐selected, sub‐therapeutic dosage, and what dosage they were taking.

The DDS group was defined as survivors who were still taking the drug in the year prior to the study while the control group had not continued to take the drug. One year was selected as the cut‐off point of a long‐term medication period, which could be easily recalled by the elderly. There were 32 in the recent drug exposure group (DDS group) and only nine in the group without recent exposure (control group). The total DDS treatment period and the periods of therapeutic and sub‐therapeutic dosage were determined to estimate the total lifetime DDS exposure as follows: \[period of therapeutic dosage (years) × 1 (tablet/day) × 365 days/year\] + \[period of sub‐therapeutic dosage (years) × self‐selected dosage per month (tablet/month) × 12 months/year\].

The severity of disability of each participant was determined based on the World Health Organization leprosy disability grading system (WHO‐DG),[11](#jcsm12074-bib-0011){ref-type="ref"}, [12](#jcsm12074-bib-0012){ref-type="ref"} which was evaluated at the beginning of one\'s leprosy history from each participant\'s medical record.

Measurements {#jcsm12074-sec-0009}
------------

### Baseline characteristics {#jcsm12074-sec-0010}

Basic anthropometric data including height and weight were measured using standard methods. Body mass index (BMI) was calculated as weight divided by the square of one\'s height (kg/m^2^). Obesity was defined as a BMI over 25 kg/m^2^.[13](#jcsm12074-bib-0013){ref-type="ref"} Waist circumference (cm) was checked at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest at the end of a normal expiration with the arms relaxed at the sides.

### Body composition {#jcsm12074-sec-0011}

Dual energy X‐ray absorptiometry (DISCOVERY‐W fan‐beam densitometer; Hologic Inc., Bedford, MA) was used to analyse body composition including lean body and fat masses. Appendicular skeletal muscle mass was calculated by obtaining the sum of the lean mass in bilateral upper and lower extremities.[14](#jcsm12074-bib-0014){ref-type="ref"} Skeletal muscle mass index (SMI, %) was calculated from appendicular muscle mass divided by total body weight.[15](#jcsm12074-bib-0015){ref-type="ref"} Regional SMI was defined as the skeletal muscle mass of each extremity normalized by total body weight (%). The cut‐off value from the fourth Korea National Health and Nutrition Examination Survey (2009) in Korean women (SMI = 23.2%) was accepted for low appendicular muscle mass.[16](#jcsm12074-bib-0016){ref-type="ref"} The participant was classified as having sarcopenic obesity if the conditions for both obesity and low appendicular muscle mass were met.[17](#jcsm12074-bib-0017){ref-type="ref"}

### Muscular strength {#jcsm12074-sec-0012}

Muscular strength was assessed using a handheld dynamometer (PowerTrack II; JTECH Medical, Salt Lake City, UT).[18](#jcsm12074-bib-0018){ref-type="ref"}, [19](#jcsm12074-bib-0019){ref-type="ref"} Maximal voluntary contractions (MVC) were assessed for bilateral shoulder abduction, hip flexion, elbow flexion, and knee extension, in that order. One of the authors (S.G.C.) checked isometric MVCs of all the participants based on the 'make and break' technique.[20](#jcsm12074-bib-0020){ref-type="ref"} Four bilateral muscle groups were tested per trial. Three trials were conducted with 5 min of rest between trials. The highest peak value among three trials was determined as MVC for each functional muscle group.[21](#jcsm12074-bib-0021){ref-type="ref"} All MVCs were normalized to total body weight (MVC/TBW).

### Physical performance and activity levels {#jcsm12074-sec-0013}

Physical performance and activity levels were measured using functional examination and questionnaires. Functional examination was conducted using the short physical performance battery (SPPB) derived from three objective physical function tests, that is, the time taken to cover 4 m at a comfortable walking speed, time taken to move as quickly as possible to standing from sitting in a chair five times without stopping, and ability to maintain balance for 10 s in three different foot positions at progressively more challenging levels.[22](#jcsm12074-bib-0022){ref-type="ref"} A score from 0 to 4 was assigned to performance on each task, with higher scores indicating better lower body function. The questionnaire to assess physical activity level was a short version of International Physical Activity Questionnaire in Korean (K‐IPAQ).[23](#jcsm12074-bib-0023){ref-type="ref"}, [24](#jcsm12074-bib-0024){ref-type="ref"}

Statistical analysis {#jcsm12074-sec-0014}
--------------------

Welch\'s *t*‐tests were used for comparison of means of anthropometric data, SMI, regional SMI, whole‐body fat mass, and MVC for each functional muscle group. The unequal variances *t*‐tests were applied because the two groups had unequal sample sizes.[25](#jcsm12074-bib-0025){ref-type="ref"} The same test was employed to compare the components of the K‐IPAQ and SPPB between the two groups. The χ^2^ test was used to compare the prevalence of low appendicular muscle mass, obesity, and sarcopenic obesity between the two groups. Pearson\'s correlation coefficient was used for analysing the relationship between total lifetime DDS exposure and sarcopenic variables. The linear by linear association test was also used to compare WHO‐DG between the two groups. PASW Statistics 18 (SPSS Inc., Chicago, IL, USA) was used for all analyses. *P*‐values \< 0.05 were considered statistically significant.

Results {#jcsm12074-sec-0015}
=======

Subjects characteristics {#jcsm12074-sec-0016}
------------------------

Thirty‐two had been taking DDS for the past 1 year and more (DDS group) and nine had not (control group). Intergroup differences in age and period since leprosy diagnosis were not significant. However, the total DDS treatment period and the period of therapeutic dose were significantly longer (53.5 ± 6.7 vs. 31.9 ± 18.0 years, *P* = 0.007; 28.1 ± 22.1 vs. 12.7 ± 14.2 years, *P* = 0.027, respectively), and total lifetime DDS exposure of the DDS group was significantly larger (11 551 ± 6109 vs. 4496 ± 4535 tablets, *P* = 0.001) in the DDS group. However, the control group had significantly milder disability (eight with WHO‐DG 0 and one with WHO‐DG 1) than the DDS group (*P* = 0.027) (*Table* [1](#jcsm12074-tbl-0001){ref-type="table-wrap"}).

###### 

Age and medical history of the DDS and control groups

                                           DDS (*n* = 32)   Control (*n* = 9)   *P*‐value[a](#jcsm12074-note-0003){ref-type="fn"}   
  ---------------------------------------- ---------------- ------------------- --------------------------------------------------- -----------------------------------------------
  Age (years)                              74.3 ± 7.8       72.7 ± 6.2          0.519                                               
  Period since leprosy diagnosis (years)   57.0 ± 8.6       55.8 ± 6.1          0.635                                               
  Total DDS‐taking period (years)          53.5 ± 6.7       31.9 ± 18.0         0.007                                               
  Period of Therapeutic dosage (years)     28.1 ± 22.1      12.7 ± 14.2         0.027                                               
  Total lifetime DDS exposure (tablets)    11 551 ± 6 109   4 496 ± 4 535       0.001                                               
  WHO disability grade                     0                16                  9                                                   0.027[b](#jcsm12074-note-0004){ref-type="fn"}
                                           1                2                   1                                                   
                                           2                7                   0                                                   
                                           3                6                   0                                                   

Data are presented as mean ± standard deviation.

DDS, 4,4′‐diamino‐diphenyl sulfone; WHO, World Health Organization.

Welch\'s *t*‐test for group differences and

linear by linear association for WHO disability grade comparison.

Comparisons of body compositional characteristics {#jcsm12074-sec-0017}
-------------------------------------------------

The DDS group showed a lower BMI (24.9 ± 2.8 vs. 27.2 ± 3.7 kg/m^2^, *P* = 0.107) and higher SMI (24.4 ± 2.7 vs. 22.6 ± 2.2%, *P* = 0.066) than the control group. The DDS group had lower prevalences of low appendicular muscle mass (34 vs. 67%, *P* = 0.082), and sarcopenic obesity (16 vs. 56%, *P* = 0.014) than those of the control group (*Table* [2](#jcsm12074-tbl-0002){ref-type="table-wrap"}). Regional SMIs were higher in the DDS group than in the control group for all four limbs. The differences were statistically significant in both dominant and non‐dominant legs (9.11 ± 1.08 vs. 8.41 ± 0.77%, *P* = 0.044 and 8.85 ± 0.85 vs. 7.92 ± 0.89%, *P* = 0.018, respectively) (*Figure* [2](#jcsm12074-fig-0002){ref-type="fig"}).

###### 

Comparisons of anthropometric data and sarcopenic indices between the DDS and control groups

                                     DDS (*n* = 32)   Control (*n* = 9)   *P*‐value[a](#jcsm12074-note-0007){ref-type="fn"}
  ---------------------------------- ---------------- ------------------- ---------------------------------------------------
  Height (cm)                        147.7 ± 6.0      147.7 ± 8.4         1.000
  Weight (kg)                        54.5 ± 8.6       59.7 ± 11.5         0.232
  BMI (kg/m^2^)                      24.9 ± 2.8       27.2 ± 3.7          0.107
  Waist circumference (cm)           82.9 ± 7.8       86.5 ± 7.1          0.237
  SMI (%)                            24.4 ± 2.7       22.6 ± 2.2          0.066
  Whole‐body fat mass (kg)           19.1 ± 5.0       22.5 ± 8.1          0.293
  Low appendicular muscle mass (%)   11/32 (34%)      6/9 (67%)           0.082[b](#jcsm12074-note-0008){ref-type="fn"}
  Obesity (%)                        14/32 (44%)      6/9 (67%)           0.224[b](#jcsm12074-note-0008){ref-type="fn"}
  Sarcopenic obesity (%)             5/32 (16%)       5/9 (56%)           0.014[b](#jcsm12074-note-0008){ref-type="fn"}

Data are presented as mean ± standard deviation.

BMI, body mass index; SMI, skeletal muscle mass index; DDS, 4,4′‐diamino‐diphenyl sulfone.

Welch\'s *t*‐test and

χ^2^ test for group differences.

![Comparisons of regional skeletal muscle mass index (SMI) of each limb between the 4,4′‐diamino‐diphenyl sulfone (DDS) and control groups. \**p* \< 0.05 by Welch\'s *t*‐test.](JCSM-7-322-g002){#jcsm12074-fig-0002}

Comparisons of muscular strength, physical performance, and activity levels {#jcsm12074-sec-0018}
---------------------------------------------------------------------------

In all the tested muscle groups, the DDS group had larger MVC/TBWs than the control group. Shoulder abductors, elbow flexors, hip flexor, and knee extensors of the non‐dominant side of the DDS survivors were significantly stronger than those of controls (2.14 ± 0.68 vs. 1.49 ± 0.48 N/ kg, *P* = 0.005; 2.85 ± 0.80 vs. 2.20 ± 0.69 N/kg, *P* = 0.029; 2.47 ± 0.76 vs. 1.96 ± 0.46 N/kg, *P* = 0.021; and 3.91 ± 1.12 vs. 2.71 ± 0.81 N/kg, *P* = 0.005, respectively) (*Figure* [3](#jcsm12074-fig-0003){ref-type="fig"}).

![Comparisons of maximal voluntary contraction of dominant and non‐dominant shoulder abductor, elbow flexor, hip flexor, and knee extensor between the 4,4′‐diamino‐diphenyl sulfone (DDS) and control groups. Muscular strength was normalized by total body weight. \**p* \< 0.05 by Welch\'s *t*‐test.](JCSM-7-322-g003){#jcsm12074-fig-0003}

Three components of the SPPB of the DDS group were higher than those of the control group, and total scores of SPPB also showed an insignificant difference between the DDS and control groups (9.3 ± 2.6 vs. 7.6 ± 3.2, *P* = 0.155) (*Table* [3](#jcsm12074-tbl-0003){ref-type="table-wrap"}). With regard to activity levels assessed using K‐IPAQ, the DDS group demonstrated longer daily walking duration (*P* = 0.005) and larger weekly walking amounts calculated from the duration and frequency of walking (*P* = 0.020) (*Table* [4](#jcsm12074-tbl-0004){ref-type="table-wrap"}).

###### 

Comparisons of physical performance by short physical performance battery between the DDS and control groups

                  DDS (*n* = 32)   Control (*n* = 9)   *P*‐value[a](#jcsm12074-note-0011){ref-type="fn"}
  --------------- ---------------- ------------------- ---------------------------------------------------
  Balance         2.8 ± 1.2        2.0 ± 1.8           0.216
  Walking speed   3.3 ± 0.9        2.9 ± 0.8           0.218
  Chair stand     3.2 ± 1.2        2.7 ± 1.3           0.308
  Total score     9.3 ± 2.6        7.6 ± 3.2           0.155

Data are presented as mean ± standard deviation.

DDS, 4,4′‐diamino‐diphenyl sulfone.

Welch\'s *t*‐test for group differences.

###### 

Comparisons of the functional activity by a short version of International Physical Activity Questionnaire in Korean between the DDS and control group

                                                 DDS (*n* = 9, 28%)   Control (*n* = 2, 22%)   *P*‐value[a](#jcsm12074-note-0015){ref-type="fn"}
  ----------------------- ---------------------- -------------------- ------------------------ ---------------------------------------------------
  Moderate activity       Frequency (day/week)   1.4 ± 2.5            1.1 ± 2.4                0.753
  Duration (minute/day)   22.6 ± 49.9            40.0 ± 79.4          0.547                    
                          Amount (minute/week)   107.6 ± 233.8        200.0 ± 435.8            0.555

                          DDS (*n* = 24, 77%)    Control (*n* = 6, 67%)   *P*‐value[a](#jcsm12074-note-0015){ref-type="fn"}   
  ----------------------- ---------------------- ------------------------ --------------------------------------------------- -------
  Walking                 Frequency (day/week)   4.4 ± 3.1                4.0 ± 3.3                                           0.764
  Duration (minute/day)   43.8 ± 46.4            14.4 ± 15.1              0.005                                               
  Amount (minute/week)    254.5 ± 323.3          94.4 ± 99.6              0.020                                               

Data are presented as mean ± standard deviation.

The subject numbers denoted by '*n*' are the number of subjects who gave positive responses to each question.

DDS, 4,4′‐diamino‐diphenyl sulfone.

Welch\'s *t*‐test for group differences.

Correlations with total lifetime DDS exposure {#jcsm12074-sec-0019}
---------------------------------------------

The total lifetime DDS exposure significantly correlated with regional SMI of non‐dominant leg (*r* = 0.379, *P* = 0.015). SMI and regional SMI of dominant leg also showed positive correlations with DDS dosage (*r* = 0.254, *P* = 0.109, and *r* = 0.280, *P* = 0.076, respectively) (*Table* [5](#jcsm12074-tbl-0005){ref-type="table-wrap"} and *Figure* [4](#jcsm12074-fig-0004){ref-type="fig"}).

###### 

Correlations between total lifetime 4,4′‐diamino‐diphenyl sulfone exposure and body composition and muscle strength

                                   Pearson\'s correlation coefficient (*r*)   *P*‐value[a](#jcsm12074-note-0017){ref-type="fn"}
  -------------------------------- ------------------------------------------ ---------------------------------------------------
  BMI                              −0.159                                     0.321
  SMI                              0.254                                      0.109
  Regional SMI                                                                
  Dominant arm                     −0.035                                     0.827
  Non‐dominant arm                 0.006                                      0.969
  Dominant leg                     0.280                                      0.076
  Non‐dominant leg                 0.379                                      0.015
  Muscular strength                                                           
  Dominant shoulder abductor       0.040                                      0.811
  Dominant elbow flexor            0.155                                      0.347
  Dominant hip flexor              0.090                                      0.587
  Dominant knee extensor           0.128                                      0.439
  Non‐dominant shoulder abductor   0.174                                      0.282
  Non‐dominant elbow flexor        0.139                                      0.392
  Non‐dominant hip flexor          0.170                                      0.293
  Non‐dominant knee extensor       0.204                                      0.206

BMI, body mass index; SMI, skeletal muscle mass index.

Pearson\'s correlation with total lifetime 4,4′‐diamino‐diphenyl sulfone exposure.

![Correlations between total lifetime 4,4′‐diamino‐diphenyl sulfone (DDS) exposure and sarcopenic indices: (A) skeletal muscle mass index (SMI), (B) regional SMI of the dominant leg, and (C) regional SMI of the non‐dominant leg.](JCSM-7-322-g004){#jcsm12074-fig-0004}

Discussion {#jcsm12074-sec-0020}
==========

Body composition, muscular strength, physical performance, and activity level were examined in all the community‐ambulating elderly female leprosy survivors with mild or no physical impairment living in a leper colony comprising of two villages. Survivors who had been taking DDS had larger regional SMI in both legs, lower prevalence of sarcopenic obesity, greater muscular strength of non‐dominant shoulder abductors, elbow flexors, hip flexor, and knee extensors, and higher walking scores in K‐IPAQ than survivors not on the medication. Most importantly, there was a significant dose--response relationship between total lifetime DDS exposure and regional SMI of the lower extremity. To our knowledge, this is the first report to reveal different sarcopenic status in humans associated with DDS medication.

Quantity and quality of skeletal muscle {#jcsm12074-sec-0021}
---------------------------------------

Although the statistical significance was not high, the SMI of the DDS group tended to be higher than that of the control group (24.4 ± 2.7 vs. 22.6 ± 2.2%, *P* = 0.066). It is of note that the DDS group had more disabilities than the control group according to the disability status in leprosy as shown in *Table* [1](#jcsm12074-tbl-0001){ref-type="table-wrap"}, which could have caused survivors receiving DDS to lead more sedentary lives and be more vulnerable to having low appendicular muscle mass. Further, the findings of lower prevalence of low appendicular muscle mass and sarcopenic obesity in the DDS group are suggestive of potential anti‐sarcopenic effects of DDS.

The quantitative superiority of skeletal muscles in the DDS group was reinforced by comparing muscle quality. The non‐dominant shoulder abductor, elbow flexor, hip flexor, and knee extensor were significantly stronger in the DDS group. This finding is especially interesting because there are several supporting reports[26](#jcsm12074-bib-0026){ref-type="ref"}, [27](#jcsm12074-bib-0027){ref-type="ref"}, [28](#jcsm12074-bib-0028){ref-type="ref"} that loss of muscle power, called dynapenia,[26](#jcsm12074-bib-0026){ref-type="ref"} correlates more closely with physical function and risk for disability than reduction of skeletal muscle mass.[29](#jcsm12074-bib-0029){ref-type="ref"}, [30](#jcsm12074-bib-0030){ref-type="ref"} Considering that sarcopenia is regarded as a secondary outcome of dynapenia,[26](#jcsm12074-bib-0026){ref-type="ref"}, [27](#jcsm12074-bib-0027){ref-type="ref"} it is remarkable that DDS may have preventive effects on both sarcopenia and dynapenia. Stronger muscular strength in the DDS‐taking survivors was also reflected in functional performance scores and levels of physical activity.

Dose--response relationship of DDS in anti‐sarcopenia {#jcsm12074-sec-0022}
-----------------------------------------------------

To reveal the anti‐sarcopenic effects of the drug, correlations between the total lifetime DDS exposure and sarcopenic variables were obtained. Regional SMI of non‐dominant leg showed a significant correlation with total DDS exposure and that the correlation of low extremity muscle mass with the walking function[31](#jcsm12074-bib-0031){ref-type="ref"} corroborates the results of comparative analyses demonstrating higher quantity (regional SMI) and better quality (muscular strength) in lower extremities. Considering that the current study was not a controlled clinical trial and that the number of participants was not large enough to overcome several hidden confounders, a positive correlation between DDS exposure and regional SMI supports the hypothesis that DDS has anti‐sarcopenic effects.

Target of DDS in skeletal muscle {#jcsm12074-sec-0023}
--------------------------------

Even though the target of DDS in eukaryotic cells is not fully understood, pyruvate kinase (PK) is the best candidate. It has been suggested that DDS might inhibit the biochemical activity of PK and the *pyk*‐1 gene, the PK‐encoding gene, which are mainly expressed in skeletal muscles in animals.[9](#jcsm12074-bib-0009){ref-type="ref"} They also proposed that the inhibition of PK activity might lead to down‐regulation of the entire tricarboxylic acid cycle as a compensatory mechanism. This suggested mechanism is also supported by the finding that PK deficiency in humans results in hemolytic anaemia,[32](#jcsm12074-bib-0032){ref-type="ref"} the most common side effect of DDS.

In contrast, some investigators showed that the serum level of pyruvate in leprosy patients who had been taking DDS was higher than that of the control group.[33](#jcsm12074-bib-0033){ref-type="ref"} If DDS is inhibiting PK activity, the pyruvate level should have been down‐regulated. Another conflicting result comes from the study of *pyk*‐1 deletion mutant (*ok1754*) worms.[9](#jcsm12074-bib-0009){ref-type="ref"} The *ok1754* worms treated with DDS lived longer than untreated *pyk*‐1 mutant animals, but just as long as normal worms treated with DDS. This indicates that there must be additional DDS targets for extending the lifespan. Further investigations for identifying the interaction between DDS and PK are needed.

Limitations of this study {#jcsm12074-sec-0024}
-------------------------

There are several limitations of this study. First, the number of participants was relatively small to obtain the representativeness of total leprosy population. However, considering that all of the community‐ambulating female elderly survivors in the colony were recruited, the results of this study would be reflective of general characteristics in those leprosy regions. In addition, unequal sample sizes between the DDS and control groups (32 vs. 9) could also limit the statistical power. To address the issue, Welch\'s *t*‐test, an adaptation of Student\'s *t*‐test for unequal variances and unequal sample sizes, was utilized.[25](#jcsm12074-bib-0025){ref-type="ref"} Second, health behaviours such as taking medicines regularly or walking frequently might have been confounding factors. Because the DDS group had more disabilities than the control group at the onset of the disease, they might have been more concerned about health‐related issues, which could have raised their tendency to take DDS and to increase their physical activities, resulting in higher muscle mass and better muscle quality. Third, the authors defined sarcopenia based only on muscle mass reduction in contrast to recent consensus recommendations[34](#jcsm12074-bib-0034){ref-type="ref"}, [35](#jcsm12074-bib-0035){ref-type="ref"} suggesting inclusion of hand grip strength and gait speed. While we checked all participants\' gait speeds as one of the tasks of SPPB, hand grip strength was unreliable to measure because some of the subjects had minor hand deformities as sequelae of leprosy. Therefore, we applied the classical definition of sarcopenia. Instead of hand grip strength, we tested muscle strength of major joints (shoulder, elbow, hip, and knee) and analysed them quantitatively. Lastly, with the genuine limitation of a cross‐sectional study, it is hard to establish a strong causal relationship between DDS and sarcopenia at the present stage. Therefore, further randomized controlled trials are needed.

Conclusions {#jcsm12074-sec-0025}
===========

This study shows that DDS‐taking leprosy survivors have a significantly lower prevalence of sarcopenic obesity and increased skeletal muscle mass, muscular strength, and walking activity than leprosy survivors not taking DDS. There was a dose--response relationship between total lifetime DDS exposure and skeletal muscle mass of the lower extremities. These findings may suggest one possible hypothesis on the potential sarcopenia‐preventive effects of DDS. Albeit by a cross‐sectional study, this is the first clinical investigation to implicate that sarcopenia can be influenced by a repositioned drug. Further controlled clinical trials are required to confirm the precise effects of DDS.
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